A Retrospective Analysis of the Italian Medicines Agency's Evaluation of Real World Evidence in Innovativeness Assessments

How is real-world evidence shaping patient access to medicines in Italy? We’re excited to share that our latest research will be presented by Diego Civitelli #ISPORAnnual in Montréal. Diego investigates how the Italian Medicines Agency (#AIFA) incorporates real-world data when granting innovative status to new drugs—a designation that can unlock funding and accelerate patient access. With billions of euros and patient outcomes at stake, understanding how decision-makers perceive and apply real-world evidence is more important than ever. Join us on Thursday, 15 May from 6:00 – 7:00 PM to learn more.

Please click here to download the poster
‍
Don’t forget to subscribe to our newsletter below for the latest company updates, recently published HTA guidance, industry insights, and more!

‍